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Genome evolution predicts genetic interactions in
protein complexes and reveals cancer drug targets
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Genetic interactions reveal insights into cellular function and can be used to identify drug
targets. Here we construct a new model to predict negative genetic interactions in protein
complexes by exploiting the evolutionary history of genes in parallel converging pathways in
metabolism. We evaluate our model with protein complexes of Saccharomyces cerevisiae and
show that the predicted protein pairs more frequently have a negative genetic interaction
than random proteins from the same complex. Furthermore, we apply our model to human
protein complexes to predict novel cancer drug targets, and identify 20 candidate targets with
empirical support and 10 novel targets amenable to further experimental validation. Our study
illustrates that negative genetic interactions can be predicted by systematically exploring
genome evolution, and that this is useful to identify novel anti-cancer drug targets.
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K
nowledge of how proteins interact with each other to exert
their function is crucial for understanding how disruption
of interactions can lead to disease1,2 and in the
development of treatments. In recent years, several system-level
maps of protein complexes have been constructed from physical
interaction data3–5 to initialize understanding of the functional
relationships between proteins. These studies are important in
identifying which proteins are linked to each other in biological
processes6. Yet, these maps do not directly reveal how the
proteins interact with each other. More speciﬁcally, they do not
provide information about whether the interaction between two
proteins is symmetric, in which both proteins are equally
important in the function of a protein complex, or whether the
interaction is asymmetric, in which one protein can function in
the absence of the other protein, but not vice versa (Fig. 1a). One
example of such asymmetry is the cyclin–Cdc28 complex where
the function of the cyclin, Cln1p, depends on the Cdc28 kinase,
but not vice versa. The function of Cln1p depends on Cdc28p as
transcriptional activation of CLN1 requires an active Cdc28
kinase7. The function of Cdc28p, however, does not depend on
Cln1p as the presence of Cln2p compensates for Cln1p’s absence
to activate Cdc28p (ref. 8). Thus, there is a functional asymmetry
between Cln1p and Cdc28p, where Cln1p depends on Cdc28p
and not vice versa (Cln1p-Cdc28p). Similarly, there is
asymmetry between Cln2p and Cdc28p (Cln2p-Cdc28p). This
example shows the relationship between functional asymmetry
and what is called a negative genetic interaction, where mutations
(for example, knockout) of two genes (for example, CLN1 and
CLN2) reduce the ﬁtness much more strongly than would be
expected based on the decline in ﬁtness of each gene individually9.
The concept of negative genetic interactions is very valuable in the
development of therapeutic treatments for diseases that can be
treated by selectively depleting cells with a disease-causing
mutation. Especially promising are the discoveries of cancer
drugs that target proteins having synthetic lethal interactions with
mutated oncogenes or tumour-suppressor genes10,11. The
mechanism underlying this treatment is that inhibiting these
genes separately is relatively harmless in a normal cell, while it is
lethal to a cancer cell as it causes a lethal double mutant with
mutated oncogenes/tumour-suppressor genes. Thus, targeting
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Figure 1 | Functional asymmetry and negative genetic interactions are linked. (a) Protein A and B have an asymmetric functional relationship, where
the function of A depends on B but not vice versa. The asymmetry between protein A and B can be owing to the presence of protein C, which can
compensate for a mutant of A. In such a scenario, proteins A and C are predicted to have a negative genetic interaction. (b) Functional asymmetry between
enzyme A and B involved in a branched pathway in a metabolic network (A depends on B, but not vice versa: A-B). Nodes and arrows represent
metabolites and reactions, respectively. The asymmetric relationship is owing to a converging reaction catalysed by enzyme C, which can compensate for
A’s absence. Thus, enzyme A and C are likely to have a negative genetic interaction. (c) Flowchart to predict negative genetic interactions from genome
evolution within a three-member protein complex (protein A, B and C). The blue arrow represents the functional asymmetry between two genes inferred
from genome evolution. The blue line represents that there is no evolutionary evidence for a functional asymmetry between two genes. Here, both gene
A and C are predicted to have functional asymmetry with B, while gene A and C are predicted not to have functional asymmetry.
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these genes can kill the cancer cells while leaving the normal cells
relatively unaffected. Prioritizing drug targets in such an approach,
by predicting negative genetic interactions between the mutated
oncogenes/tumour-suppressor genes and other proteins, is,
however, not trivial.
Discovering negative genetic interactions mainly depends on
laborious and speciﬁc experiments, which can be expensive and
time-consuming, partially because of the explosion of the number
of pairwise gene combinations. Several computational approaches
have been developed to predict genetic interactions by integrating
multiple types of functional genomic data, such as synthetic
lethality data, physical interaction data and co-expression
data12,13. These approaches, however, strongly depend on
species-speciﬁc empirical genetic interaction data as input and
therefore do not allow predictions for other species where genetic
interaction data are largely unavailable.
Here, we aim to predict negative genetic interactions in protein
complexes via the concept of functional asymmetry, which we
infer from genome evolution. The example of the cyclin-Cdc28
complex showed that functional asymmetry and negative genetic
interaction are linked. This linkage can also be illustrated by
enzyme relationships in metabolism. Enzymes in converging
pathways have asymmetric relationships with an enzyme in an
outgoing pathway14,15 (Fig. 1b). Consequently, the enzymes in
converging pathways can have negative genetic interactions, as
they can compensate for each other’s absence. Analogous to
metabolism, we expect that two proteins in a complex with
asymmetry to a third protein will have a negative genetic
interaction (Fig. 1a,c). Importantly, the functional asymmetry
between enzymes in metabolism is indeed reﬂected in genome
evolution15,16.
On the basis of these prior studies, we have developed an
evolutionary model to predict asymmetric functional relation-
ships and negative genetic interactions in protein complexes in
S. cerevisiae17. Our model predicts that almost 75% of the protein
complexes in S. cerevisiae contain functionally asymmetric protein
pairs. By integrating the information of predicted asymmetry in
protein complexes, we show an up to twofold increase in the
predictive power for negative genetic interactions relative to
randomly chosen protein pairs from a complex. Moreover, our
results show a twofold increase in prediction precision compared
with an alternative model18. After mapping negative genetic
interaction predictions from yeast to human, as well as a direct
application to human protein complexes, we predict 20 cancer
drug targets with empirical support and 10 completely novel
targets not yet experimentally examined. Our study shows that
higher-order functional relationships can be predicted by
systematically exploring genome evolution, thereby providing a
framework to interpret protein complex function with broad
application to medical genetics.
Results
Functional asymmetry occurs frequently in protein complexes.
In order to examine if patterns in genome evolution can be used
to predict negative genetic interactions, we ﬁrst predicted asym-
metry between protein pairs (A–B) in protein complexes from
evolutionary analysis. We constructed a model integrating 11
evolutionary variables from the reconstructed ancestral states on
a phylogenetic tree of 373 species (Fig. 2 and Methods). For
instance, evolutionary asymmetry between proteins A and B is
inferred from the occurrence of multiple evolutionary loss events
where only one of the two genes was lost in the descendant while
both genes were present in the ancestor. If A is more frequently
lost than B, then A is expected to be functionally dependent on B
(A-B, see Fig. 2a,b, scenario f1). The model was trained on a set
of functionally asymmetric enzyme pairs in the genome-scale
metabolic network of S. cerevisiae19 to predict the dependency
between the two enzymes (see Methods for detail).
Using a tenfold cross-validation, the model showed a correct
classiﬁcation rate of 64.4% and an area under the receiver
operator characteristic curve of 0.7 (see Methods for details;
Supplementary Fig. S1). It should be noted that the performance
of the model becomes worse when using a simpler model with
only single gain and loss events (Supplementary Fig. S1). We next
asked how frequently functional asymmetry occurs in empirically
determined protein complexes from S. cerevisiae17. Our analysis
predicts that 71% (6,145 out of 8,711) of the protein pairs in these
protein complexes are functionally asymmetric. Furthermore,
B75% (307 out of 409) of the protein complexes are found to
have at least one predicted functionally asymmetric protein pair
(Supplementary Fig. S2).
Empirical evidence for functional asymmetry. The high
frequency of predicted functional asymmetry triggers the ques-
tion to what extent our predictions are biologically meaningful.
To answer this question, we asked whether predicted asymmetry
is reﬂected in genome-scale empirical data. We ﬁrst examined
asymmetry in gene essentiality. For a predicted functionally
asymmetric pair (A-B) where only one of the proteins is
essential, we expect protein B to be the essential one. To test this,
we examined those predicted asymmetric pairs where only one of
the encoding proteins is essential and quantiﬁed to what extent
the predicted asymmetry is consistent with asymmetry in gene
essentiality. Our analysis reveals that 72% (1,071 out of 1,497) of
the asymmetric pairs (A-B) are consistent with asymmetry in
gene essentiality, that is, if one of the two genes is essential, it is B
(Fig. 3a; one-tailed Fisher’s exact test; Po2.2e 16).
Many predicted asymmetric pairs have, however, no asym-
metry in gene essentiality, simply because the majority of proteins
are not strictly essential under standard laboratory conditions
(that is, glucose-rich medium)4. Approximately 40% of the
predicted asymmetric pairs are composed of two non-essential
genes. Nevertheless, even when proteins are non-essential they
can still contribute to ﬁtness and result in signiﬁcant growth
defects after a gene knockout20,21. Similarly to the gene
essentiality analysis, we expected that if one of the two proteins
in a predicted asymmetric pair (A-B; both non-essential) has a
stronger growth defect, it would be protein B. To test this, we
examined 511 predicted asymmetric pairs where two non-
essential proteins cause different growth defects, and quantiﬁed
the consistency between the predicted and empirical functional
asymmetry. As expected, 63% (322 out of 511) of the cases are
consistent (Fig. 3a; one-tailed Fisher’s exact test; P¼ 1.40e 04),
that is, the predicted independent protein B has a stronger growth
defect when knocked out. This consistency is robust at various
cutoffs on empirical growth defect differences (ranging from
0.0001–0.3). Notably, the level of consistency increased from 63
to 67% when we increased the cutoff to 0.3, that is, where growth
defect difference is largest. These results show that the
evolutionary model is able to capture asymmetric functional
relationships in protein complexes. ESCRT-I, a protein complex
functioning in cargo selection in the multivesicular body (MVB)
sorting pathway, is one example where the predicted functional
asymmetry is supported by solid empirical evidence (Fig. 3b).
Empirical evidence for negative genetic interactions. An
asymmetric functional relationship observed between two pro-
teins A and B can also be linked to a type of relationship known
as a negative genetic interaction9. The reasoning behind this is
that B may not depend on the presence of A, because of the
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presence of another protein C that compensates for A’s absence.
We asked whether our evolutionary model is capable of
predicting such negative genetic interactions in multi-member
protein complexes. We speciﬁcally focused on triplets where
protein A, B and C are predicted to have an evolutionary fan-in
motif (Fig. 1a). This motif is characterized by (i) A and C depend
on B, but not vice versa and (ii) A does not depend on C and vice
versa. This motif is analogous to converging pathways in
metabolism, in which there is a mechanistic explanation for
the compensatory effect between A and C (Fig. 1b). We there-
fore ﬁrst investigated to what extent converging metabolic
pathways15,21 show negative genetic interactions20–28 as a proxy
for compensation, that is, double mutants cause more severe
growth defects than expected from the two single mutants.
Indeed, enzyme pairs in converging pathways show a threefold
enrichment in negative genetic interactions compared with non-
converging enzyme pairs (Fig. 3c; one-tailed Fisher’s exact test;
P¼ 2.42e 11).
Given this result, we expect that in cases where we predict a
fan-in motif within a protein complex, the A and C proteins have
negative genetic interactions with each other. To address this, we
compared fan-in A–C pairs with randomly chosen pairs from the
same protein complex (that is, non-motif A–C pairs). Our results
reveal that the fraction of negative genetic interactions increases
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Figure 2 | Evolutionary variables to predict functional asymmetry. (a) Depiction of an evolutionary event. It shows a loss of gene A in the descendant (d)
when both A and B are present in the ancestor (a). (b) Evolutionary variables used for the Bayesian classiﬁer. The evolutionary variables across history of
the dependent protein A in an asymmetric pair (A-B) can be expressed via 11 measures, listed in the ﬁrst columns of two boxes. Of these 11, 6 count the
number of times that a dependent protein A is gained or lost independently of B, including 2 that are expected to occur less often and 4 that are expected
to occur more often for a dependent protein than for an independent protein. The remaining ﬁve measures are fractions that express relative frequencies of
two evolutionary scenarios between A and B. f1, f2, f3 and f4 are expected to be larger than 0.5; f5, that weighs f4 with the absolute difference between two
gain events of A, is expected to be larger than 0. The six evolutionary and the ﬁve relative frequencies all contribute to the prediction of functional
asymmetry (Supplementary Fig. S1). (c) Schematic presentation of predicting the functional asymmetry in a protein pair (A–B). ATAN classiﬁer was trained
on functionally asymmetric enzyme pairs in the metabolic network14. For a protein pair (A–B), the 11 evolutionary variables (Fig. 2b) are used to predict the
conditional probability that A is functionally independent (a1) or dependent (a2). A is likely to be independent if a14a2, or dependent if a1oa2.
Subsequently, A can be predicted as independent, dependent or unclassiﬁed by applying a cutoff on probability (a¼max(a1, a2), see Methods). The same
procedure is applied to protein B. By combining the prediction of both, A–B can be either A-B where A is dependent and B is independent, B-A where A
is independent and B is dependent, or no evidence for asymmetry when A and B have any other combination of predicted relationship.
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by 50% when applying the evolutionary motif (from 23.5–35.8%;
one-tailed Fisher’s exact test; P¼ 0.00085; Fig. 3c). It should be
noted that this enrichment of negative genetic interactions is not
owing to the functional complementation by homologous genes
resulting from intra-complex gene duplications, as the results
are hardly affected by removing homologous gene pairs (from
22.7–33.0%; one-tailed Fisher’s exact test; P¼ 0.012; Fig. 3c). As
protein complexes are not necessarily active in standard
laboratory conditions where genetic interactions have been
measured, we expected that our test underestimates the predictive
power. Indeed, when selecting for only protein complexes that are
active in the cell (that is, B is essential) the predictive power even
doubles (from 24.5–49.2%; one-tailed Fisher’s exact test; P¼ 4.39
e 05; Fig. 3c). Thus, the evolutionary model can predict protein
pairs that have a negative genetic interaction signiﬁcantly and
substantially more often than random pairs from protein
complexes. To further assess the performance of our model, we
compared the prediction precision and sensitivity of it with a
model by Pandey et al.18 by mapping their results to the protein
complexes. This model has the highest known prediction
accuracy and is also independent on genetic interaction
information as input. Interestingly, our model has a twofold
higher prediction precision (precision—TruePositives/
TruePositivesþ FalsePositives: 0.36 versus 0.18; sensitivity—
TruePositives/TruePositivesþ FalseNegatives: 0.47 versus 0.78).
Notably, our model still has a precision of 40.3 when
parameterized to the same sensitivity as Pandey’s model
(Supplementary Fig. S3).
In total, our model predicted 273 A–C pairs in evolutionary
fan-in motifs in S. cerevisiae protein complexes, for most of which
(60%) a genetic interaction has not been measured. However, to
provide empirical evidence for the predicted negative interac-
tions, we exploited available genetic interaction data in Schizo-
saccharomyces pombe and Drosophila melanogaster via orthology
deﬁnitions from STRING7.0 (ref. 29). Following this approach,
we found that for ten out of our A–C pairs a genetic interaction
has been experimentally found in either in S. pombe or in
D. melanogaster and, as expected, most cases (8/10) show a nega-
tive genetic interaction in those species (Supplementary Data 1).
Negative genetic interactions reveal cancer drug targets. The
screen for negative genetic interactions has been shown to be a
valuable strategy in the search for candidate cancer drug tar-
gets10,30. The common approach is to ﬁnd proteins that have a
negative genetic interaction with either an oncogene or a tumour-
suppressor gene. As mutations in these genes cause cancer, the
idea is that mutations in their negative genetic interaction partner
would inhibit cancer cells to grow (that is, synthetic lethality) and
leave normal cells relatively viable. Although a number of
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Figure 3 | Asymmetric functional relationships and negative genetic interactions. (a) Empirical support for predicted functional asymmetry in gene
essentiality49 and, for non-essential genes, in the growth defect of single-gene knockout20,21. For predicted asymmetric pairs (A-B), the fraction fAB
(f01¼ n01/(n01þ n10)), where 0¼ non-essential or no ﬁtness defect and 1¼ essential or substantial growth defect is expected to be larger than 0.5 (fraction
in pairs with no asymmetry). (b) One example of predicted functional asymmetry with experimental support. ESCRT-I is composed of four members,
Vps23p, Vps28p, Vps37p and Mvb12p. Mvb12p (blue subunit) is predicted to functionally dependent on Vps23p, Vps28p and Vps37p (red) and not vice
versa. Structural studies revealed that the functionally dependent subunit, Mvb12p, is a structural stabilizer, which changes the ESCRT-I core complex
(Vps23p, Vps28p and Vps37p) from a fan-shaped structure (upper panel) to an elongated structure (lower panel)57. First, the dependency of Mvb12 on the
core complex is supported by the fact that Mvb12p is unstable in cells lacking any of the other ESCRT-I subunits58. Second, that Vps23p, Vps29p and
Vps37p do not strictly depend on Mvb12p is validated by the ﬁndings that certain MVB sorting pathways, such as carboxypeptidase S (CPS) and Ste2
sorting, are effective even if Mvb12p is absent58,59. However, loss of function of Vps23p, Vps28p or Vps37p results in a complete block of the MVB
pathway58. (c) Enrichment of negative genetic interactions in fan-in motif A–C pairs. The fraction of negative genetic interaction is deﬁned as
f¼Nneg/(NnegþNposþNnoInteraction). P-values in (a) and (c) were calculated with a one-tailed Fisher’s exact test and visualized with an asterisk (*)
that stands for a P-value o0.05.
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promising examples have been reported to target cancer cells via
synthetic lethality10,11,30, discovering genetic interactions by
experimental approaches is very labour intensive. Therefore, we
asked whether our model captures conserved genetic interactions
between S.cerevisiae and other species like D. melanogaster, such
that it can serve as a framework to establish genetic interactions
for medical genetics. Based on the orthologue proﬁles from
STRING7.0 (ref. 29), we found 90.1% (246 out of 273) of the
predicted fan-in motifs in yeast are conserved in D. melanogaster,
that is, all three genes in a fan-in motif are present in
D. melanogaster. Of these, nine have been examined for genetic
interaction in D. melanogaster31–33, and all show negative genetic
interaction (note, 7/9 have also been found in S.cerevisiae). This
suggests that our model can be used to predict negative genetic
interactions in other species, such as mouse or human, which
could provide a basis for prioritizing drug targets.
To achieve the highest coverage, we combined two strategies to
predict cancer drug targets: (i) by using orthology mapping from
predicted negative interactions from yeast to human and (ii) by a
direct application of our model to human protein complexes34,35.
By using orthologues of the genes in the predicted fan-in motifs
in yeast, we predicted B250 novel negative genetic interaction
pairs in human, of which 36 involve a cancer-related gene
(oncogene or tumour-suppressor gene)36. Notably, most of these
pairs (83.4%, 30/36) have not been reported before as negative
genetic interactions. To apply our method directly on human
protein complexes34,35, we ﬁrst trained our model with functional
asymmetric enzyme pairs from the human genome-scale
metabolic network37 (see Methods). Then we used the model to
predict negative genetic interaction pairs. Totally, we predicted
1,012 gene pairs with negative genetic interactions of which 57
involve a cancer-related gene. Thus, totally, we predicted 93 cases
with cancer-related genes. The genes that have a negative genetic
interaction with these cancer-related genes are potential drug
targets if they are essential in cancer cells while non-essential in
normal cells. By examining gene essentiality in cancer cells38 and
non-essentiality in normal cells of Mus musculus (mouse),
D. melanogaster or Danio rerio (zebraﬁsh) (Supplementary
Data 2), we found that 30 out of the 93 involve promising
cancer drug targets (pink column in Fig. 4; Supplementary Data
2). Among these 30 prioritized targets, 20 have been found to be
essential in at least one cancer type, that is, breast, ovary or
pancreas, and non-essential in a model organism (pink column in
Fig. 4). Interestingly, most of these predicted targets (16/20) are
essential in the exact cancer type where their negative genetic
interaction partners, the cancer-related genes, are reported to be
mutated or overexpressed (blue column in Fig. 4; Supplementary
Data 2). This empirical evidence suggests that the lethality of the
cancer cells by knockdown of the predicted target gene is actually
caused by a lethal double mutant of the predicted targets and the
cancer-related gene. As expected, when considering only those
cases for which essentiality is measured in cancer cells (that is,
60þ 18 cases, green column in Fig. 4), the predicted targets
are more likely to be essential in cancer and non-essential
in normal cells compared with non-motif gene pairs
(fractionE_cancerþNE_normal¼ 0.26 versus 0.12, one-tailed Fisher’s
exact test; P¼ 4.8e 04). The remaining ten targets have not yet
been experimentally examined for the essentiality in cancer cells:
six are non-essential in M. musculus or D. melanogaster and four
have not yet been measured (pink column in Fig. 4;
Supplementary Data 2). Thus, we predicted 30 potential drug
targets in total, that is, 20 with empirical support of essentiality in
cancer cells and 10 novel ones (Table 1 and Supplementary
Data 2). To give an example, one of the predicted drug targets,
TLE1, has a negative genetic interaction with the cancer-related
gene, HDAC1 (ref. 39). HDAC1 failed to be a direct drug target as
the inhibition of mouse Hdac1 caused embryonic lethality in
normal development40. TLE1, on the other hand, has been found
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Figure 4 | Prioritized cancer drug targets with empirical support. Thirty prioritized cancer drug targets. The numbers in red represent the 30 promising
targets. The numbers in grey represent the genes that failed to be targets as they are either non-essential in cancer cells or are essential in normal cells.
In total, 93 genes are predicted to have a negative genetic interaction with a cancer-related gene. By examining gene essentiality in cancer and non-
essentiality in normal cells, we prioritized 30 cancer drug targets. Twenty cases are essential in at least one cancer type, that is, breast, ovary or pancreas
and non-essential in normal cells. Experimentally detected genetic variation/overexpression of the cancer-related gene and the RNA interference of the
predicted targets in the same cancer type or the same cancer cell line were combined suggesting a double mutant. For most of these (16/20), there is
empirical evidence that the cancer-related gene is mutated in either the same cancer type or the same cancer cell line as the predicted targets (blue
column). For six cases that are conﬁrmed to be non-essential in normal cells, the essentiality in cancer still needs to be examined experimentally. For four
cases, the essentiality in both cancer cells and normal cells is not yet measured (red numbers in the pink column).
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to be essential in several types of cancer cells38 and non-essential
in D. melanogaster41. In addition, TLE1 and HDAC1 have a
conﬁrmed negative genetic interaction in D. melanogaster41,
which makes TLE1 a promising drug target for further analysis.
Another example is the predicted interaction between NSUN2
and FBXW7 (Fig. 5). NSUN2 is experimentally found to be
essential in cancer cells42, and FBXW7, a tumour-suppressor
gene, has been found to be mutated in cancer cells43. In normal
cells, NSUN2 and FBXW7 both function to regulate cellular
differentiation via two different mechanisms. FBXW7 regulates
cell differentiation by inhibiting c-Myc44 and proteins in Notch
pathway45, and NSUN2 functions to maintain normal cell
differentiation when activated by LEF1/b-catenin complex,
which is part of Wnt pathway46,47. It has been found that the
loss of FBXW7 results in elevated expression of c-Myc44, which
results in an upregulation of NSUN2 (ref. 48). As a result, NSUN2
stabilizes the mitotic spindle in fast cell proliferation in cancer cell
growth42. Thus, targeting NSUN2 can kill cancer cells while
leaving normal cells relatively unaffected, owing to the
compensatory FBXW7–Notch pathway. This is further
supported by the non-essentiality of NSUN2 in normal mouse
model47.
Discussion
Even though various experimental techniques are available to
study protein function, understanding their functions within
protein complexes and their relationships between each other in a
complex remains a challenge. Here, we have developed a model to
predict functional relationships within protein complexes using
the evolutionary history of genomes in terms of gene gain and
loss events. We ﬁrst focused on the relationships in which the
function of one protein A depends on the function of another
protein B, but in which the reverse relationship is much weaker.
We predicted such asymmetry by integrating various evolu-
tionary scenarios, such as, gene B is more frequently gained
across evolutionary history in the absence of gene A than vice
versa. So, B can occur without A, but A cannot occur without
B. To validate the method, we showed that the predicted
functional asymmetry is consistent with various sources of
empirical evidence, such as asymmetry in gene essentiality and
single-knockout growth defects. However, one-third of the gene
pairs in the same complex with asymmetry in gene essentiality
(633/2,130) have not been captured by our model. Perfect
prediction can, however, not be expected, because it is strictly
based on complete gene loss and gain. Our model may therefore
beneﬁt from more ﬁne-scale evolutionary events, such as the
incorporation of mutation rates. Thus, in species where both A
and B are still present, there might be asymmetry in the extent to
which they have diverged at the sequence level from their
respective ancestors. Second, the essentiality and growth defect
data sets4,49 cover speciﬁc nutrient environments, which might
not be experienced by species in our evolutionary model. Such
differences in physiological conditions may result in different
genome evolution and, as such, it could negatively affect model
predictions.
Interestingly, functional asymmetric relationships can be used
to predict negative genetic interactions in those cases where
multiple proteins, for instance, A and C, have asymmetry with the
same protein B. The underlying idea is that functional asymmetry
is owing to the fact that A and C can compensate for each other’s
absence. Indeed, we have shown that our model increases the
Table 1 | List of predicted cancer drug targets.
Cancer-related genes Predicted target genes with empirical
evidence: essential in cancer cell
non-essential in normal cell
Novel predicted target genes: *unknown essentiality in normal
cell and cancer cell **non-essential in normal cell and
unknown essentiality in cancer cell
DDB2|FBXW7|EML4 LSMD1 PPIB|PPIC|PPID**
HDAC5|HDAC6 NTG1|GNL3L|SSTR5**
PPWD1|PPIH|PPIE
KIAA0564
NSUN2|NSUN5
BCL3|NOTCH2|CDKN2C|NFKB2 HDAC5|HDAC6 PPIB|PPIC|PPID**
PPWD1|PPIH|PPIE
MSI2 DENR
CREBBP|EP300|BRD4|
PBRM1|BRD3|TRI-M24|SMARCA4
USP12|USP22|USP30 USP45**
PIK3CA USP12|USP22|USP30 USP45**
HDAC1 TLE1
DDX5|DDX6|DDX10|EIF4A2 ATAD2*
PBRM1 ACTG1
MED12 MED14
HIST1H4I H3F3A
EZH2 EED
RPN1 MAGT1
PIK3R1 ESR1
SMAD4 JUND
CCNE1 SKP1
CREBBP KAT2B
FANCF C17orf70*
FANCC FANCB*
FANCF FANCB*
SEPT9 SEPT11**
Twenty predicted cancer drug targets with experimental evidence (second column) and ten novel targets (third column). The grey-shaded rows show targets predicted by using orthology mapping and the
rows without show targets predicted directly from human protein complexes. Each grey-shaded cell represents a Clusters of Orthologous Group (COG) of cancer-related genes or predicted drug targets.
The ﬁrst column shows the cancer-related genes. The second column shows 20 predicted drug targets with empirical evidence where each gene is essential in at least one cancer cell and non-essential in
model organisms. The third column shows ten novel targets for which the essentiality in cancer cells has not yet been measured.
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predictive power for negative genetic interactions in S. cerevisiae
protein complexes by 50–100% relative to random protein pairs
from the same complex. Moreover, we predict many novel genetic
interactions, of which eight have been experimentally veriﬁed in
S. pombe and D. melanogaster. Although this number is not high,
this is not unexpected given that genome-scale genetic interaction
screens have only been performed in S. cerevisiae20 and
S. pombe50. Moreover, only one screen under standard nutrient
condition has been conducted for these two species, respectively,
and it remains to be seen how genetic interactions vary across
other nutrient conditions. It would therefore be interesting to
apply our model to study the variation of interactions across
conditions, for example, to re-evaluate evolutionary theories that
are based on adaptive landscapes (for example, robustness against
mutations in single environments) initialized by studies on
metabolism51. One strategy would be to integrate gene expression
proﬁles across a wide range of nutrient conditions with protein
complex data to remove unexpressed subunits from protein
complexes and thus obtain condition-speciﬁc complexes. In
addition, condition-speciﬁc essentiality proﬁles4 could be used to
constrain the independent protein (B) to be essential. As a result,
one could predict fan-in motifs that are speciﬁc for a given
condition. Our ﬁnding that the predictive power of negative
genetic interactions doubles when incorporating essentiality
supports such a strategy.
Various recent studies have stated that the discovery of
(negative) genetic interactions is a very important step towards a
full understanding of the genetic basis of complex diseases and
providing a framework to discover drug targets52–54. Even though
there are a number of very promising candidate drug targets
discovered by using genetic interactions10,11, effectively
identifying them experimentally remains a major challenge. In
contrast to other prediction models12,13,18, our model does not
depend on genetic interaction screens, which are available in a
very limited number of species. Thus, our model can be applied to
predict genetic interactions in species even when no empirical
genetic interaction information is available. Moreover, compared
with Pandey et al.18, our model has a signiﬁcantly higher
prediction precision. Our approach is therefore useful to
prioritize drug candidates. We found 20 cancer drug targets for
which there is empirical evidence that they are essential in
tumour cells and predicted ten novel drug targets. Notably, the
majority (25/30) has not been measured in yeast or predicted by
other computational approaches13,18. These targets are promising
given the empirical evidence that all are essential in at least one
cancer type, such as breast, pancreas or ovarian cancer, while
non-essential in model organisms. Future studies should reveal to
what extent these targets are (i) non-essential in the same human
healthy cell type, (ii) conserved across different tumour types and
(iii) vulnerable for drug compounds.
In the light of medical genetics, the presented approach can be
applied to mammals when future protein–protein interaction
networks become available for cancer and normal cell lines. This
would allow for more speciﬁc predictions of cancer drug targets.
FBXW7
NSUN2
Notch
Wnt
LEF1/
β-catenin
NSUN2
c-Myc
Cell proliferation
FBXW7 Notch
Wnt
LEF1/
β-catenin
c-Myc
Cell proliferation
 Mutant  in
mouse
Normal cell
No lethal phenotype
Notch
Wnt
LEF1/
β-catenin
NSUN2
c-Myc
Cell proliferation
Cancer cell
FBXW7
mutation
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Normal differentiation Normal differentiation
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Figure 5 | A cancer drug target revealed by predicted negative genetic interactions. NSUN2 is predicted to have a negative genetic interaction with
FBXW7. Targeting NSUN2 can kill the cancer cells while leaving the normal cell relatively unaffected. In normal cells, the tumour-suppressor gene
FBXW7 has functional redundancy with NSUN2 in regulating cellular differentiation. In cancer cells, loss of function of FBXW7 results in an elevated
expression of c-Myc. Activation of c-Myc results in the upregulation of NSUN2 that is essential for cell proliferation. Owing to a synthetic lethality between
FBXW7 and NSUN2, targeting NSUN2 kills cancer cells, while leaving normal cells relatively unaffacted. A solid line represents an active protein, for
example, FBXW7 inhibiting the accumulation of NOTCH1 and NOTCH3 in normals cells45. A red cross illustrates the disruption of the function of a protein,
that is, transcriptional regulation of NSUN2 by c-Myc2 is repressed in normal cell, or the disruption of a cellular function, that is, differentiation or
proliferation.
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It should be noted that although we focused on protein
complexes, our model might be used to predict interactions for
any gene pair, as long as they are known to have a functional
relationship between them. Taken together, this study shows that
negative genetic interactions in protein complexes can be
predicted by genome evolution, which has an application in
searching for drug targets and in understanding human diseases.
Methods
Protein complexes. Four hundred and nine and 2,468 protein complexes of
S. cerevisiae17 and human34,35 were used to predict negative genetic interactions
within them, respectively. For each protein complex, all pair-wise combinations
of proteins were generated as input for our evolutionary model.
Reconstruction of ancestral states. We used the presence and absence of
orthologous genes across 373 species obtained from STRING 7.0 orthologous
groups29 to reconstruct ancestral states of genes. We inferred the most
parsimonious ancestral presence/absence states of each gene by using a rooted
trifurcation (Achaea/Eukaryote/Eubacteria) phylogenetic tree of 373 species. All
results were obtained using a gain/loss cost ratio of 2/1 and a delayed transition
assumption (DELTRAN) in PAUP55. From the ancestral state reconstruction, we
generated 11 evolutionary variables as inputs to the following classiﬁcation step.
The integration of these 11 evolutionary variables gives the highest correct
classiﬁcation rate compared with alternative integrations of evolutionary variables.
For each gene pair A–B, we examined the following six evolutionary scenarios:
(i) both genes were absent in the ancestor (a) and one was gained in the descendant
(d) (a00_d10 or a00_d01), (ii) the presence of only one gene in the ancestor was
maintained in the descendant (a10_d10 or a01_d01), (iii) both genes were present
in the ancestor and one was lost in the descendant (a11_d01 or a11_d10), (iv) a
gain of one gene occurred when the other was present in the ancestor (a01_d11
or a10_d11), (v) only one gene was present in the ancestor and was lost in the
descendant (a10_d00 or a01_d00) and (vi) only one gene was present in the
ancestor and was lost in the descendant while the other gene was gained (a10_d01
or a01_d10) (Fig. 2b).
For gene A, we also calculated ﬁve fractions that reﬂect evolutionary asymmetry
between A and B, f1: a11_d01/(a11_d01þ a11_d10), f2: a01_d11/(a01_d11þ
a10_d11), f3: a01_d01/(a01_01þ a10_d10), f4: a01_d11/(a01_d11þ a00_d10) and
f5: a01_d11*[a01_d11 a00_d10þ 1]/[a01_d11þ a00_d10].
Evolutionary information to predict asymmetry of gene pairs. First, we
reconstructed ancestral states for 2,400 directionally coupled enzyme pairs (func-
tional asymmetry; A-B) in the yeast metabolic network19 and generated the 11
evolutionary variables. Directional coupling was found by constraining the reaction
ﬂux of one to a ﬁnite value followed by minimizing and maximizing another, and
vice versa14. A-B is found when the minimum ﬂux through A is zero while the
maximum is a ﬁnite value (when constraining B to a ﬁnite ﬂux), and the minimum
and maximum ﬂux through B is unequal to zero when A is constrained to a ﬁnite
value. Thus, the activity of A depends on the activity of B, but not the reverse
(A-B). Each of the 11 evolutionary variables is a predictor for functional
asymmetry between an enzyme pair (A-B) as the 11 variables of a dependent
A differ from those of an independent B. More speciﬁcally, for evolutionary events
(i) and (ii), A is expected to occur less often than the independent B. For the other
four evolutionary events, A is expected to occur more often than the independent
B. Furthermore, we expect f1, f2, f3 and f4 to be larger than 0.5, and f5 to be larger
than 0 for asymmetric functional relationships (Supplementary Fig. S1).
Given the fact that these 11 variables are not independent from each other, we
used a Tree Augmented Naı¨ve Bayes (TAN) classiﬁer to integrate these predictors.
The TAN classiﬁer relaxes the assumption of independence of input variables. The
classiﬁer is trained on the 2,400 directionally coupled enzyme pairs using WEKA56.
The classiﬁer estimates conditional probabilities of one gene being independent
(a1) or dependent (a2), where a1þ a2¼ 1. The gene is predicted to be either
independent (if a14a2) or dependent (if a1oa2) with a conditional probability (a),
where a¼max (a1, a2). To predict the functional relationship in protein complexes
by this classiﬁer, we ﬁrst reconstructed ancestral states for 8,711 protein pairs
(A–B) and generated the 11 evolutionary variables for A and B. The functional
relationship of A–B is determined as follows: (i) the classiﬁer generates class
predictions for A with a probability estimate (a); (ii) identifying predictions with
high conﬁdence by a cutoff on a (any prediction where a is smaller than the cutoff
remains unclassiﬁed); (iii) protein B is predicted in the same way; and (iv)
combining the classiﬁcation result of A and B, A–B is predicted as functionally
asymmetric when A is dependent and B is independent or vice versa.
Otherwise, there is no evidence for functional asymmetry and the pair becomes
unclassiﬁed (Fig. 2c).
Gene essentiality. Essentiality data were obtained from MIPS database49. If a gene
is annotated as both essential and non-essential in different sources, the essentiality
is assigned according to the majority rule. Otherwise, a gene was marked as
ambiguous.
For predicted asymmetric pairs (A-B), we counted cases where only B is
essential (n01) and cases where only A is essential (n10). For symmetric pairs (A–B),
it is expected that n01 is equal to n10. To test against the null hypothesis of no
relationship between predicted functional asymmetry and asymmetry in essenti-
ality, we subjected the 2 2 contingency table of essential/non-essential versus
symmetric/asymmetric to a one-tailed Fisher’s exact test.
Growth defect of single-gene knockouts in rich medium. Growth defect of
single-gene knockouts was obtained from two studies20,21, which cover 75% of all
genes in S. cerevisiae. A growth defect was considered as substantial if a gene
knockout causes a growth defect 410% (ref. 4).
For predicted asymmetric pairs with two non-essential genes (A-B), we
counted cases where knockout of B causes a more severe growth defect (n01) and
cases where knockout of A causes a more severe growth defect (n10). For functional
symmetric pairs (A–B), it is expected that n01 is equal to n10. To test against the
null hypothesis of no relationship between predicted functional asymmetry and
asymmetry in growth defect, we subjected the 2 2 contingency table of n01/n10
versus symmetric/asymmetric to a one-tailed Fisher’s exact test.
Negative genetic interactions in the metabolic network. We obtained fan-in
motif A–C pairs for metabolic reactions (Fig. 1c) by using ﬂux coupling between
enzymes within the genome-scale metabolic network of S. cerevisiae (see above).
The fan-in motif A–C pairs have two characteristics: (i) A and C both depend on a
third essential protein B (A-B and C-B) and (ii) the A–C pair is uncoupled. For
experimental validation, we used an empirical genetic interaction proﬁle from
Szappanos et al. (obtained from the Supplementary Information21). If no
signiﬁcant genetic information was available for a pair of genes, we determined it as
not measured and excluded it from the analysis.
To test against the null hypothesis of no enrichment of negative genetic
interactions in fan-in motif A–C pairs, we summarized the motif A–C/non-motif
A–C pairs versus with/without negative genetic interaction in a 2 2 contingency
table and subjected it to a one-tailed Fisher’s exact test.
Negative genetic interactions in protein complexes. We obtained A–C pairs
with evolutionary fan-in motifs (Fig. 1a) from asymmetric functional relationships
predicted by the TAN model (Fig. 2c). The evolutionary fan-in motif is char-
acterized by (i) A and C depend on B, but not vice versa and (ii) A does not depend
on C and vice versa. To ensure A–C is not an asymmetric pair, we applied the
cutoff for signiﬁcant functional asymmetry to a4¼ 0.7. At this cutoff, the correct
classiﬁcation rate increases the most at the smallest cost of samples size
(Supplementary Fig. S4).
Genetic interaction data were obtained from BioGRID31. As BioGRID does not
specify whether the genetic interaction of a gene pair has been measured, we
integrated the original data from nine high-throughput data sets20–28, to generate a
list of measured genetic interactions (either positive, negative or no interaction). If
a pair of genes has both a negative and a positive genetic interaction, the genetic
interaction was assigned according to the majority rule.
To test against the null hypothesis of no enrichment of negative genetic
interactions in pairs with a fan-in motif, we summarized motif A–C/non-motif
A–C versus with/without negative genetic interaction in a 2 2 contingency
table and tested using a one-tailed Fisher’s exact test.
Prediction of cancer drug targets. We mapped predicted negative genetic
interactions from yeast to human via orthology from STRING7.0 (ref. 29). To
retrieve drug targets, we ﬁrst mapped cancer gene information from the Cancer
Genome Project36 to the predicted genetic interactions to extract predictions
involving one oncogene or tumour-suppressor gene. Then we mapped gene
essentiality measurements in cancer from Marcotte et al.38 to the predictions. In
addition, non-essentiality of the drug targets in normal cells/tissues was examined
by literature mining covering M. Musculus, D. melanogaster or D. rerio.
To predict targets directly from human protein complexes, we trained our
model on functional asymmetric enzyme pairs from the human genome-scale
metabolic network37 via Flux Coupling Analysis (see also above for yeast and
Burgard et al.14). Subsequently, we used experimentally determined protein
complexes34,35 to predict human-speciﬁc negative genetic interactions via the
evolutionary fan-in motifs. Finally, we examined gene essentiality among predicted
drug targets in cancer and normal cells/tissues as outlined above.
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